Cargando…

Evaluation of apamin effects on myelination process in C57BL/6 mice model of multiple sclerosis

Multiple sclerosis (MS) is a demyelinating disease that causes chronic inflammation in the central nervous system. The aim of this study was to investigate the effects of apamin administration on myelination process. MS was induced by feeding cuprizone pellets (0.2%) for 6 weeks (demyelination phase...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohammadi-Rad, Maedeh, Ghasemi, Nazem, Aliomrani, Mehdi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6827192/
https://www.ncbi.nlm.nih.gov/pubmed/31798659
http://dx.doi.org/10.4103/1735-5362.268203
_version_ 1783465265037574144
author Mohammadi-Rad, Maedeh
Ghasemi, Nazem
Aliomrani, Mehdi
author_facet Mohammadi-Rad, Maedeh
Ghasemi, Nazem
Aliomrani, Mehdi
author_sort Mohammadi-Rad, Maedeh
collection PubMed
description Multiple sclerosis (MS) is a demyelinating disease that causes chronic inflammation in the central nervous system. The aim of this study was to investigate the effects of apamin administration on myelination process. MS was induced by feeding cuprizone pellets (0.2%) for 6 weeks (demyelination phase) followed by normal feeding for additional 2 weeks (remyelination phase). Briefly, C57BL/6 male mice were randomly divided into six groups. Group 1, received the regular food pellets. Group 2 contained two subgroups of 6 animals each (n = 2 × 6). First group received cuprizone for 6 weeks and the sacrificed while the second group after 6 weeks of cuprizone, received no treatment for additional 2 weeks. Group 3 (co-treatment group) was composed of two subgroups of 6 animals each (n = 2 × 6). Both subgroups received apamin (100 μg/kg) intraperitoneally twice a week for 6 weeks. First subgroup terminated at this time and the second subgroup was fed normal diet for two additional weeks. Group 4 (post-treatment, n = 6) received apamin (100 μg/kg) intraperitoneally twice a week for 2 weeks after cuprizone secession. Groups 5 and 6 (vehicle, n = 6 in each group) received phosphate buffered saline as the vehicle of apamin during demyelination and remyelination phase. At the end of each phase, mice were deeply anesthetized and perfused. Groups 5 and 6 (vehicle) received PBS as the vehicle during both phases. Mice were anesthetized, perfused with PBS through their heart, and their brains were removed. Brain sections stained with luxol fast blue and the images were analyzed. Apamin co-treatment significantly increased the myelin content as compared to the cuprizone group. Also, mild elevation in the myelinated areas was observed with apamin post-treatment in comparison with remyelination phase. Our results revealed that apamin prevents myelin destruction more significantly as compared to remyelination process. This observation explains the possible role of apamin in inhibiting the activation of the microglia cells than stimulation of the oligodendrocytic precursor cells.
format Online
Article
Text
id pubmed-6827192
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-68271922019-12-03 Evaluation of apamin effects on myelination process in C57BL/6 mice model of multiple sclerosis Mohammadi-Rad, Maedeh Ghasemi, Nazem Aliomrani, Mehdi Res Pharm Sci Original Article Multiple sclerosis (MS) is a demyelinating disease that causes chronic inflammation in the central nervous system. The aim of this study was to investigate the effects of apamin administration on myelination process. MS was induced by feeding cuprizone pellets (0.2%) for 6 weeks (demyelination phase) followed by normal feeding for additional 2 weeks (remyelination phase). Briefly, C57BL/6 male mice were randomly divided into six groups. Group 1, received the regular food pellets. Group 2 contained two subgroups of 6 animals each (n = 2 × 6). First group received cuprizone for 6 weeks and the sacrificed while the second group after 6 weeks of cuprizone, received no treatment for additional 2 weeks. Group 3 (co-treatment group) was composed of two subgroups of 6 animals each (n = 2 × 6). Both subgroups received apamin (100 μg/kg) intraperitoneally twice a week for 6 weeks. First subgroup terminated at this time and the second subgroup was fed normal diet for two additional weeks. Group 4 (post-treatment, n = 6) received apamin (100 μg/kg) intraperitoneally twice a week for 2 weeks after cuprizone secession. Groups 5 and 6 (vehicle, n = 6 in each group) received phosphate buffered saline as the vehicle of apamin during demyelination and remyelination phase. At the end of each phase, mice were deeply anesthetized and perfused. Groups 5 and 6 (vehicle) received PBS as the vehicle during both phases. Mice were anesthetized, perfused with PBS through their heart, and their brains were removed. Brain sections stained with luxol fast blue and the images were analyzed. Apamin co-treatment significantly increased the myelin content as compared to the cuprizone group. Also, mild elevation in the myelinated areas was observed with apamin post-treatment in comparison with remyelination phase. Our results revealed that apamin prevents myelin destruction more significantly as compared to remyelination process. This observation explains the possible role of apamin in inhibiting the activation of the microglia cells than stimulation of the oligodendrocytic precursor cells. Wolters Kluwer - Medknow 2019-10-04 /pmc/articles/PMC6827192/ /pubmed/31798659 http://dx.doi.org/10.4103/1735-5362.268203 Text en Copyright: © 2019 Research in Pharmaceutical Sciences http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Mohammadi-Rad, Maedeh
Ghasemi, Nazem
Aliomrani, Mehdi
Evaluation of apamin effects on myelination process in C57BL/6 mice model of multiple sclerosis
title Evaluation of apamin effects on myelination process in C57BL/6 mice model of multiple sclerosis
title_full Evaluation of apamin effects on myelination process in C57BL/6 mice model of multiple sclerosis
title_fullStr Evaluation of apamin effects on myelination process in C57BL/6 mice model of multiple sclerosis
title_full_unstemmed Evaluation of apamin effects on myelination process in C57BL/6 mice model of multiple sclerosis
title_short Evaluation of apamin effects on myelination process in C57BL/6 mice model of multiple sclerosis
title_sort evaluation of apamin effects on myelination process in c57bl/6 mice model of multiple sclerosis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6827192/
https://www.ncbi.nlm.nih.gov/pubmed/31798659
http://dx.doi.org/10.4103/1735-5362.268203
work_keys_str_mv AT mohammadiradmaedeh evaluationofapamineffectsonmyelinationprocessinc57bl6micemodelofmultiplesclerosis
AT ghaseminazem evaluationofapamineffectsonmyelinationprocessinc57bl6micemodelofmultiplesclerosis
AT aliomranimehdi evaluationofapamineffectsonmyelinationprocessinc57bl6micemodelofmultiplesclerosis